Study Condition(s): Type 2 Diabetes

A Study of U-500 Insulin (Humulin LY041001) in Participants With Type 2 Diabetes

Study Alias: IBHG

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02588950 {{ currentLocaleObject.registryAnchorText }}

Recruiting Recruiting

Study Purpose

The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18 years
74 years

Time Commitment

Your participation could last from 7 to 14 weeks and include 5 visits to the study center
  • Participant must have type 2 diabetes mellitus (T2DM)

  • Participant must be currently using U-100 insulin analog with a total daily dose of greater than 200 units and have a total daily dose of less than or equal to 3.0 units per kilogram; basal; premixed; or basal/bolus by any injection device

  • Participant must be on concomitant antihyperglycemic agent(s) which may include metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone, glucagon like peptide (GLP)-1 receptor agonists which must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)

  • Participant must not have type 1 diabetes mellitus (T1DM) or other types of diabetes mellitus

  • Participant must not have known hypersensitivities or allergies to insulin

  • Participant must not have used U-500R within 3 months prior to screening

  • Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia

Where to Participate

0 locations are currently available of 1 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.